A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1

Inclusion Criteria: * Subject has a histologically documented diagnosis of prostate cancer * Subject was surgically castrated at least 3 months prior to study inclusion or has been pharmacologically castrated for a minimum of 3 months prior to study inclusion. * Subject must meet one of the following PSA criteria: * A PSA value of ≥20ng/mL (µg/L) obtained 12 months prior to study inclusion OR * A 50% rise in PSA values with a minimum rise of 1.0 ng/ml (µg/L), within 6 months prior to study inclusion OR * A rise in PSA defined by 2 sequential increases in PSA values. inclusion. There must be at least 2 weeks between each qualifying PSA value. * Subjects who have received anti-androgen therapy must have a documented withdrawal period prior to study inclusion. * For a subject who has withdrawn from anti-androgen therapy LESS than 6 months prior to study inclusion, one of the following criteria is ALSO required for eligibility: * Following the completion of the anti-androgen withdrawal period, one post-withdrawal PSA value must be higher than the last pre-withdrawal PSA value OR * Following the completion of the anti-androgen withdrawal period, if the subject's PSA value decreased, then he can still qualify if two increases in PSA values (as described in 4c) are documented after post-withdrawal nadir. * At the time of screening the subject has no distant metastatic disease. Exclusion Criteria: * Subject is less than 19 years of age. * Subject has a PSA value \< 1.0 ng/mL at screening * Subject currently has evidence of distant metastases. * Subject has not, in the opinion of the investigator, a life expectancy greater than 12 months. * Subject has a local recurrence and is a candidate for local salvage therapy * Subject having previously received therapy \[including radiation, steroids, radionuclides (such as rhenium, strontium or samarium), cryotherapy or cytotoxic chemotherapy\] for prostate cancer are ineligible as defined below: * Subjects who received previous cytotoxic chemotherapy or radionuclide therapies are ineligible * Subjects who received therapy to the prostatic bed (external beam radiotherapy, brachytherapy or cryotherapy) within 6 months prior to study entry are ineligible. * Subjects who received radiation therapy to any lesion outside the prostate bed more than 6 months after castration or hormone initiation are ineligible. * Subjects who received steroids for the treatment of prostate cancer within 6 months prior to study entry are ineligible. * Subjects having previously received opioid analgesic therapy. * Subjects has received any of the following within 4 weeks of study entry: * Cyproterone acetate, ketoconazole, PC-SPES or other hormonally active therapies (with the exception of GnRH agonists or antagonists). * An investigational product * Subject is on a concurrent steroids or immunosuppressive therapy for chronic inflammatory disease. * Subject has had other malignancies within the previous 5 years with the exception of non-melanoma skin cancer. * Subject has a score \>1 on the ECOG Performance Scale (see Appendix I) * Subject has an inadequate hematologic function * Subject has inadequate liver function. * Subject has a creatinine clearance \<40 mL/min * Subject has a known history of cardiovascular disability status of New York Heart Association Class ≥2. * Subject has a history of uncontrolled asthma * Subject has autoimmune disease(s) * Subject has active infection(s) * Subject is receiving antiretroviral therapy. * Subject has received blood transfusion within 8 weeks of study inclusion. * Subject has a clinically significant, unstable, uncontrolled disease that could be adversely affected by study participation. * Subject has known allergy to shellfish